Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

- Strong European and Rest of the World Sales

- Proprietary Product Sales Increase, Portfolio Expanded - Company Provides Updated Adjusted Calendar 2008 EPS Guidance of $2.75 -

$3.05

MONTVALE, N.J., May 8 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today reported net earnings of $23 million, or $0.21 per share, on revenues of $608 million for the quarter ended March 31, 2008. The current quarter results compare with prior year net earnings of $12 million, or $0.11 per share, on revenues of $597 million. On a non-GAAP basis, adjusted earnings per share were $0.57 for the first quarter of 2008, as compared to $0.73 for the prior year period. A reconciliation of GAAP-based earnings per share to adjusted earnings per share is presented in the table at the end of this press release.

"While our results for the first quarter did not meet our expectations, we believe that these results will improve in the second half of the year and demonstrate the value of expanding our operations and markets outside the U.S.," said Bruce L. Downey, Barr's Chairman and CEO. "Strong sales growth in Europe and the Rest of the World (ROW) was driven by growth in the key markets of Germany, Russia and Poland. As expected, sales of our U.S. generic contraceptive portfolio decreased but are expected to grow from this level with the anticipated launch of generic Yasmin(R). During the quarter, we expanded our other generic U.S. product portfolio with the launch of generic versions of Fosamax(R) and Kytril(R) and continued to record strong year-over- year sales growth of our Fentanyl Citrate product. Proprietary sales increased year-over-year, driven by our Plan B(R) and SEASON
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... 2015 BioLight Life Sciences ... "Company"), a firm that invests in, manages and ... announced today that presentations highlighting its IOPtiMate™ system ... at the Ophthalmology Futures European Forum and the ... & Refractive Surgeons ("ESCRS"), both taking place in ...
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is ... attending Pharma Ed Resources upcoming educational seminar and training session on Extractable & ... timely conference will provide Updates & Case Studies on the Latest Compliance Implications ...
(Date:9/1/2015)... , September 2, 2015 ... auf die Forschung und Entwicklung neuartiger Therapien ... chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält vom ... dass sein neues Medikament patentiert wird. Das ... Allergien bei Kindern verhindert und Entzündungen vorbeugt.   ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... EMERYVILLE, Calif., Nov. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ... at the Credit Suisse 18th Annual Healthcare Conference on ... a.m. Pacific Time). Interested parties may access a ... http://www.onyx-pharm.com/view.cfm/32/Event-Calendar , It is recommended ...
... BOZEN, Italy, November 4 Health Robotics ... i.v.SOFT Workflow Engine at,the American Society of Health-System Pharmacists, ... of the i.v.SOFT Workflow Engine,Health Robotics becomes the first ... automation solution to fill the void of automated process ...
... 4 ThromboGenics NV,(Euronext Brussels: THR), a biopharmaceutical company focused ... today issuing a,business update for the period ending 30 September, ... of ThromboGenics, said: , "ThromboGenics, clinical ... happy to have completed patient enrolment,for the US Phase III ...
Cached Biology Technology:Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 2Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 3ThromboGenics NV - Q3 2009 Business Update 2ThromboGenics NV - Q3 2009 Business Update 3ThromboGenics NV - Q3 2009 Business Update 4ThromboGenics NV - Q3 2009 Business Update 5ThromboGenics NV - Q3 2009 Business Update 6ThromboGenics NV - Q3 2009 Business Update 7
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... may not be enough to experience significant health benefits, ... activity such as walking alone is not likely going ... that occasionally elevate the intensity," said Dr. Vicki Harber, ... presented recently at the American College of Sports Medicine ...
... sepsis, a fast-moving blood infection that is a leading ... illness unleashes a powerful inflammatory response that can quickly ... within days. , With a narrow window of opportunity ... typically rush to prescribe powerful antibiotics, even before laboratory ...
... complete with her brood of some 20 eggs and 2 ... part anatomy including legs and eyes. , The research team ... Siveter from Oxford, Mark Sutton from Imperial College London and ... made a digital image of the fossil - an ostracod ...
Cached Biology News:Walking not enough for significant exercise benefits 2Gene chip technology shows potential for identifying life-threatening blood infection 2Gene chip technology shows potential for identifying life-threatening blood infection 3Gene chip technology shows potential for identifying life-threatening blood infection 4
ANTI S. ENTERID LPS...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Request Info...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Biology Products: